...there is no reason for NVCR's jettison upward, especially with no news or rumors. Then, top it off with the CEO selling $11.7 million of shares. It's illogical.
I am not a fan of NVCR, but in the last few months they did get a second approval, mesothiolomia, and also a positive early opinion in Germany for reimbursement (something NWBO could not get).